An ambispective, observational real-world study of TTFields for treatment of chinese patients with newly diagnosed or recurrent/progressive glioblastoma
Abstract Background Glioblastoma is the most common and aggressive central nervous system malignancy with poor prognosis. Tumor-Treating Fields (TTFields), approved in China in May 2020, represents a significant advancement in GBM treatment. Leveraging the extensive real-world data accumulated in the Chinese Medical Information and Big Data Association (CHMIA) database, this study aims to assess clinical outcomes of Chinese patients with glioblastoma on TTFields therapy. Methods This ambispective, observational study assessed post-marketing safety (data cut-off: November 15, 2021) and effectiveness (data cut-off: May 18, 2024) of TTFields in Chinese patients with newly diagnosed glioblastoma (ndGBM) and recurrent glioblastoma (rGBM). Safety outcomes included incidence and severity of skin adverse events (AEs); effectiveness was measured by overall survival (OS) and landmark OS rates. Results Of 648 patients screened for this study, 315 were eligible and enrolled for analysis (ndGBM: n = 210; rGBM: n = 105). In the ndGBM cohort, the median OS was 19.9 months (95% CI: 13.4–24.8), with a 12-month OS rate of 63.5% (95% CI 54.8–71.0). In the rGBM cohort, the median OS was 8.1 months (95% CI 5.3–9.8), and 3-month and 6-month OS rates were 80.2% (95% CI 70.4–87.1) and 58.7% (95% CI 47.0–68.7), respectively. Most treatment-emergent AEs (TEAEs), including skin TEAEs, were mild to moderate (Grade 1–2). Conclusions This study provided the largest real-world dataset to-date on TTFields in Chinese patients with glioblastoma. These patients showed survival outcomes similar to those in prior pivotal studies, without new safety concerns identified, supporting its use in Chinese glioblastoma population.
Authors
- Yi Yang (ORCID: https://orcid.org/0000-0002-4091-8532)
- Yongping You (ORCID: https://orcid.org/0000-0003-4753-5515)
- Jianmin Wu (ORCID: https://orcid.org/0000-0002-0999-9194)
- Xiaomin Yang (ORCID: https://orcid.org/0000-0002-5593-5108)
- Wenjie Guo (ORCID: https://orcid.org/0000-0001-8506-3905)
- Ma Wb
- Ruijun Xing
- Wei Zhang (ORCID: https://orcid.org/0000-0001-7800-3189)
- Xiang Li (ORCID: https://orcid.org/0000-0003-2454-9666)
- Liu Y (ORCID: https://orcid.org/0009-0004-3901-1652)
- T Jiang
- F Li
- Yu Wang
- Yonggao Mou
- Hua Feng
- Jiayu Fu
- Gang Li
- Guanglong Huang
- Junxia Zhang
- Hui Zhu
- Guangyuan Hu
- Xiaoguang Qiu
- Guanzhang Li
- Jianmei Hou
- Chun Wang
- Qing Mao
- Xia He
- Juan Dong
- Yuanyuan Chen
- Man Hu
- Xiang Wang
- Zhiyong Qin
- Songtao Qi
- Fuyi Liu
- Zhong Wang
- Yang Wang
- Kai Shu
- Jun Wan
Institutions
- Army Medical University (CN)
- Sun Yat-sen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sichuan University (CN)
- Peking Union Medical College Hospital (CN)
- Soochow University (CN)
- West China Hospital of Sichuan University (CN)
- Shanghai Medical Information Center (CN)
- Shandong Tumor Hospital (CN)
- Beijing Institute of Neurosurgery (CN)
- Chinese Institute for Brain Research (CN)
- Jiangsu Cancer Hospital (CN)
- Southwest Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- First Affiliated Hospital of Soochow University (CN)
- Beijing Tsinghua Chang Gung Hospital (CN)
- Shanghai Clinical Research Center (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Huashan Hospital (CN)
- Tongji Hospital (CN)
- Qilu Hospital of Shandong University (CN)
- Jiangsu Provincial Hospital of Traditional Chinese Medicine (CN)
- Shandong First Medical University (CN)
- Huazhong University of Science and Technology (CN)
- Southern Medical University (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2026-04-27
- DOI
- https://doi.org/10.1093/noajnl/vdag110
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00